The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an "eye…
Page H16From§Eachthe morning edition — 12 November 2026
FDA found mold in GLP-1 drug factories, then three weeks later warned the drugs can cause blindness.

As it ran on the front
Walk me through it. Just — start at the beginning and walk me through it, the day the inspectors went into those factories, because there's a word in my notes from that day I want to come back to exactly once, right at the end, and the word is mold.
I wrote this down. Just a second — here it is. October 15th. FDA inspectors, two factories, both in China, both making components that go into the GLP-1 drugs — the weight-loss shots, the diabetes shots. "Gross contamination," the report says. Bugs. Two factories, not one. I checked that twice, because I didn't want to be the guy who exaggerates it down to one and gets caught.…
…(cont) There's a second date in the same notebook. November 9th. Same autumn, different page. The FDA required the drugmakers — required, not asked — to put a new warning on those same drugs. Not about bugs this time. About the eyes. A condition with a longer name than I can say without the page open, something about the optic nerve, and both wire services that Monday reached for the same plain phrase for what it can do: sudden blindness.
Substantial number. Out of millions who were already swallowing it, for the diabetes or for the weight, before November 9th ever arrived. I don't have a count of how many of those millions started before the warning existed. I only have the order the two dates come in — the drug first, the warning after.
Twenty-five days. I did that math twice, out in the garage, with a flashlight in one hand and a calendar app in the other, because I didn't trust myself with just one. October 15th to November 9th is twenty-five days. Three weeks and four more. Not a month — I almost wrote "a month" the first time, and that's not what it says, so I crossed it out.
While I had the flashlight, I looked at the fan belt on the car, the one that's been fraying since August. I noticed it the same afternoon I noticed it. I didn't wait twenty-five days to tell my wife not to take it to the store that week. I don't know if a factory floor runs on the same clock as a car hood. I'm only telling you how fast the noticing went, in my garage, with my belt.
One more page. Both stories from November 9th — two different outlets, same Monday — use the word "rare" for the eye condition. I couldn't find it stamped there. What I found is the reporting using the word to describe the condition — their word, telling us what the notice does, not the notice's own word, quoted. So I'm crossing out where I had it the other way. I should've been more careful with that the first time through.
Excuse me — one more thing, before you go. Twenty-five days sits between those two dates. The first one was about bugs in the factory. The second one was about blindness in the patient. Same drugs, both ends. When you picture that gap — the twenty-five days — where does your picture start? At the warning, on November 9th? Or three weeks earlier than that, back at the mold?
“They found bugs and mold in the factories making these pills in October, and it took until November to tell anybody the pills might blind them — same drugs, three weeks apart. Millions of people are already swallowing this stuff for diabetes and weight loss, and the warning landed after the prescription, not before. That's not a glitch in the paperwork, that's the paperwork working exactly as slow as it's built to.”
“Look, three weeks is practically overnight for a federal agency, you should be thanking them for moving fast. And the factory inspection and the eye warning are two completely separate timelines, totally unrelated findings — wait, did I just connect them by saying that in the same sentence? Forget I said that.”
The receipts
When a medication is prescribed to millions of people, even an uncommon complication can affect a substantial number of individuals.
GLP-1 drugs may increase the risk of NAION, a rare optic nerve condition that can lead to sudden vision loss. It has no known treatment.
· FDA inspectors found bugs, mold at two Chinese factories that make GLP-1 weight-loss drugs: report from the morgue, 15 Oct 2026
This page is a back-issue: the story as it ran, receipts as they were. The current edition is at the front. The byline is a pen name for a column drafted by a machine and checked by the editor: how this is made.